Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...
The Galaxy Watch is the most mainstream of Samsung's ranges and is designed to compete directly with the Apple Watch. The ...
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...
such as sleep apnea. Share on Pinterest Trazodone is a prescription medication approved by the Food and Drug Administration (FDA) for depression. One of its key actions is regulating the ...
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...
LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.
Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback